Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In response to the pandemic 2009 A/H1N1 virus, monovalent MF59-adjuvanted vaccines were prepared. Recently, single 3.75-μg doses of MF59-adjuvanted vaccines have shown good immunogenicity in young adults. However, the immunogenicity of these vaccines has not been evaluated in dialysis patients.
Dialysis patients received a single 3.75-μg dose of MF59-adjuvanted vaccine by intramuscular injection. For immunogenicity assays, serum samples were obtained before vaccination and 28 days after vaccination. All sera were tested by hemagglutination inhibition assays.
Overall, 48 hemodialysis (HD) patients and 34 peritoneal dialysis (PD) patients were included in immunogenicity analysis. In HD patients, geometric mean titers (GMTs) were significantly increased compared with baseline GMTs in both young (aged 18–60 years) and elderly (aged ≥60 years) patients (51.2 ± 51.4 vs. 14.1 ± 20.7 in young patients, P = 0.012; 37.9 ± 73.9 vs. 6.8 ± 8.0 in elderly patients, P = 0.018, respectively). The rates of seroprotection and seroconversion were 27.6 and 17.2 % in young patients and 31.6 and 26.3 % in elderly patients, respectively. Among PD patients, GMTs were increased only in young patients (39.8 ± 51.4 vs. 6.8 ± 5.0, P = 0.001). The rates of seroprotection and seroconversion were 36.0 and 36.0 % in young patients and 11.1 and 0.0 % in elderly patients, respectively.
A single 3.75-μg dose of MF59-adjuvanted vaccine was suboptimal to elicit protective antibody response in dialysis patients. Antibody responses against vaccine were compromised especially in elderly PD patients. Trials of different vaccination protocols such as a two-dose schedule or a higher hemagglutinin antigen dose of MF59-adjuvanted vaccine are necessary for improving antibody response in dialysis patients.
- World Health Organization. DG statement following the meeting of the emergency committee. http://www.who.int/csr/disease/swineflu/4thmeetingihr/en/index.html. Accessed 1 Sept 2011.
- Nicoll A, Ammon A, Amato Gauci A, Ciancio B, Zucs P, Devaux I, et al. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health. 2010;124:14–23.
- Marcelli D, Marelli C, Richards N. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant. 2009;24:3566–72. CrossRef
- Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 2009;14:19361.
- Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med. 2006;354:1343–51. CrossRef
- Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13. CrossRef
- Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424–35. CrossRef
- Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414–23. CrossRef
- Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03(A)-adjuvant: preliminary report of an observer-blind, randomized trial. Vaccine. 2010;28:1740–5. CrossRef
- World Health Organization. Influenza pandemic preparedness and response: report by the Secretariat. http://apps.who.int/gb/ebwha/pdf_files/EB115/B115_44-en.pdf. Accessed 1 Sept 2011.
- Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA. 2008;105:10501–6. CrossRef
- Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine. 2009;27:3331–4. CrossRef
- Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol. 2011;18:1358–64. CrossRef
- Leypoldt JK. Urea standard Kt/V for assessing dialysis treatment adequacy. Hemodial Int. 2004;8:193–7. CrossRef
- Nolph KD, Moore HL, Twardowski ZJ, Khanna R, Prowant B, Meyer M, et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J. 1992;38:M139–42. CrossRef
- World Health Organization. WHO manual on animal influenza diagnosis and surveillance. http://whqlibdoc.who.int/hq/2002/WHO_CDS_CSR_NCS_2002.5.pdf. Accessed 1 Sept 2011.
- Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf. Accessed 1 Sept 2011.
- Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens. 1993;2:883–91. CrossRef
- Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int Suppl. 1993;41:S135–42.
- Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense. Nephron. 1993;63:125–31. CrossRef
- Hanquet G, Van Damme P, Brasseur D, De Cuyper X, Gregor S, Holmberg M, et al. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine. 2011;29:370–7. CrossRef
- de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2003;115:63–73.
- Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70:767–77. CrossRef
- Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103:c89–93. CrossRef
- Ramezani A, Eslamifar A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, et al. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. Int J Clin Pract. 2009;63:394–7. CrossRef
- Edey M, Barraclough K, Johnson DW. Review article: hepatitis B and dialysis. Nephrology (Carlton). 2010;152:137–45. CrossRef
- Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ. Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol. 2006;26:206–11. CrossRef
- Scharpé J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009;54:77–85. CrossRef
- Antonen JA, Hannula PM, Pyhala R, Saha HH, Ala-Houhala IO. Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000;86:56-61.
- Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003;37:71–6. CrossRef
- Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, et al., Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep. 2007;56:1–54.
- Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial. 2000;13:101–7. CrossRef
- Mulley WR, Visvanathan K, Hurt AC, Brown FG, Polkinghorne KR, Mastorakos T, et al. Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney Int. 2012. doi:10.1038/ki.2012.106 (Epub ahead of print).
- Labriola L, Hombrouck A, Maréchal C, Van Gucht S, Brochier B, Thomas I, et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant. 2011;26:1424–8. CrossRef
- Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis. 2011;57:716–23. CrossRef
- Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, Aranio D, et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol. 2011;49:2210–5. CrossRef
- Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41–8. CrossRef
- Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2010;375:56–66. CrossRef
- Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol. 2011;6:2208–14. CrossRef
- Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine. 2011;29:523–7. CrossRef
- Temiz G, Kasifoglu N, Kiris A, Ozturk S, Sahin G, Yalcin AU, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail. 2010;32:716–20. CrossRef
- Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging. 2011;28:93–106. CrossRef
- Giacchino F, Quarello F, Pellerey M, Piccoli G. Continuous ambulatory peritoneal dialysis improves immunodeficiency in uremic patients. Nephron. 1983;35:209–10. CrossRef
- Popovich RP, Moncrief JW, Nolph KD, Ghods AJ, Twardoski ZJ, Pyle WK. Continuous ambulatory peritoneal dialysis. Ann Intern Med. 1978;88:448–52. CrossRef
- Touraine JL, Touraine F, Revillard JP, Brochier J, Traeger J. T lymphocytes and serum inhibitors of cell-mediated immunity in renal insufficiency. Nephron. 1975;14:195–208. CrossRef
- Versluis DJ, Beyer WE, Masurel N, Diderich PP, Kramer P, Weimar W. Intact humoral immune response in patients on continuous ambulatory peritoneal dialysis. Nephron. 1988;49:16–9. CrossRef
- Antonen JA, Hannula PM, Pyhälä R, Saha HH, Ala-Houhala IO, Pasternack AI. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron. 2000;86:56–61. CrossRef
- Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23:1105–12. CrossRef
- Lin SY, Liu JH, Lin CC, Wang SM, Tsai CA, Chou CY, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011;29:3738–41. CrossRef
- Deans GD, Stiver HG, McElhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med. 2010;267:220–7. CrossRef
- Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, et al. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with type 2 diabetes mellitus in Korea. Diabet Med. 2011;28:815–7. CrossRef
- Fabrizi F, Dixit V, Martin P, Messa P. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011;33:815–21. CrossRef
- Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients
Clinical and Experimental Nephrology
Volume 17, Issue 2 , pp 275-283
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- End-stage renal disease
- Influenza A/H1N1
- Industry Sectors
- Author Affiliations
- 1. Division of Nephrology, Department of Internal Medicine, Pusan National University School of Medicine, Beomeo-ri, Mulgeum-eup, Gyeongsangnam-do, Yangsan, 626-770, South Korea
- 4. Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea
- 2. Division of Infectious Disease, Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, South Korea
- 3. Department of Laboratory Medicine, Pusan National University School of Medicine, Yangsan, South Korea
- 5. Medical Research Institute, Pusan National University Hospital, Busan, South Korea